Form 4 for JANX Janux Therapeutics, Inc.
Accepted 2023-11-15 00:00:00 ET · period of report 2023-11-13 · accession 0001209191-23-055349 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2023-11-15 | 2023-11-13 | JANX | Lichter Jay | Dir, 10% | P - Purchase | $5.87 | +849.9K | 849.9K | New | +$4.99M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-11-13 | P | A | 849,854 | $5.87 | 849,854 | I See footnote | — | — | (F1) The shares are directly held by Avalon BioVentures I, LP (ABV I). Avalon BioVentures GP LLC (ABV GP) is a general partner of ABV I and may be deemed to have voting and investment power with respect to the shares held by ABV I and as a result may be deemed to have beneficial ownership of such shares. Dr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the shares held by ABV I. Dr. Lichter disclaims beneficial ownership of such shares except to the extent of his actual pecuniary interest therein, if any. |